Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CFO Matthew Szot sold 9,933 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $6.97, for a total transaction of $69,233.01. The sale was disclosed in a document filed with the SEC, which is available at this link.

Cadrenal Therapeutics Stock Up 2.4%

Shares of CVKD stock opened at $6.78 on Friday. The company has a market capitalization of $15.87 million, a P/E ratio of -0.85 and a beta of 1.19. Cadrenal Therapeutics, Inc. has a 12-month low of $6.42 and a 12-month high of $22.90. The firm has a 50-day moving average price of $10.26 and a 200 day moving average price of $11.77.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.31) earnings per share for the quarter, topping the consensus estimate of ($1.55) by $0.24. As a group, research analysts expect that Cadrenal Therapeutics, Inc. will post -7.59 earnings per share for the current year.

Institutional Trading of Cadrenal Therapeutics

An institutional investor recently bought a new position in Cadrenal Therapeutics stock. JPMorgan Chase & Co. acquired a new position in shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 7,500 shares of the company’s stock, valued at approximately $103,000. JPMorgan Chase & Co. owned approximately 0.32% of Cadrenal Therapeutics as of its most recent filing with the Securities and Exchange Commission. 7.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $32.00.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.